Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Imke Satzger

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Melanoma Research|June 11, 2015
Complete remission of metastatic melanoma upon BRAF inhibitor treatment - what happens after discontinuation?Henrike Tolk, Imke Satzger, Peter Mohr, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|October 27, 2011
[For the benefit of the patient: the sentinel node excision]Imke Satzger, Martin Klein, Christoph Löser, et al.
Dermatology (Basel, Switzerland)|November 23, 2016
Characterisation of Prognosis and Invasion of Cutaneous Squamous Cell Carcinoma by Podoplanin and E-Cadherin ExpressionKristina Hesse, Imke Satzger, Vivien Schacht, et al.
Melanoma Research|March 12, 2019
Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanomaNora Möhn, Kurt-Wolfram Sühs, Stefan Gingele, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 21, 2007
Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomasRalf Gutzmer, Imke Satzger, Kai-Martin Thoms, et al.
European Journal of Cancer (Oxford, England : 1990)|February 24, 2018
Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumabImke Satzger, Philipp Ivanyi, Florian Länger, et al.
Cancer Immunology, Immunotherapy : CII|June 13, 2019
Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastasesYenny Angela, Sebastian Haferkamp, Carsten Weishaupt, et al.
Oncotarget|October 27, 2015
Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanomaImke Satzger, Lena Marks, Martin Kerick, et al.
Melanoma Research|March 4, 2017
Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanomaHanna Blasig, Carolin Bender, Jessica C Hassel, et al.
Journal of Oncology|December 31, 2020
Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor TherapyNora Möhn, Susann Mahjoub, Ralf Gutzmer, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Melanoma Research|June 11, 2015
Complete remission of metastatic melanoma upon BRAF inhibitor treatment - what happens after discontinuation?Henrike Tolk, Imke Satzger, Peter Mohr, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|October 27, 2011
[For the benefit of the patient: the sentinel node excision]Imke Satzger, Martin Klein, Christoph Löser, et al.
Dermatology (Basel, Switzerland)|November 23, 2016
Characterisation of Prognosis and Invasion of Cutaneous Squamous Cell Carcinoma by Podoplanin and E-Cadherin ExpressionKristina Hesse, Imke Satzger, Vivien Schacht, et al.
Melanoma Research|March 12, 2019
Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanomaNora Möhn, Kurt-Wolfram Sühs, Stefan Gingele, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 21, 2007
Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomasRalf Gutzmer, Imke Satzger, Kai-Martin Thoms, et al.
European Journal of Cancer (Oxford, England : 1990)|February 24, 2018
Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumabImke Satzger, Philipp Ivanyi, Florian Länger, et al.
Cancer Immunology, Immunotherapy : CII|June 13, 2019
Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastasesYenny Angela, Sebastian Haferkamp, Carsten Weishaupt, et al.
Oncotarget|October 27, 2015
Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanomaImke Satzger, Lena Marks, Martin Kerick, et al.
Melanoma Research|March 4, 2017
Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanomaHanna Blasig, Carolin Bender, Jessica C Hassel, et al.
Journal of Oncology|December 31, 2020
Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor TherapyNora Möhn, Susann Mahjoub, Ralf Gutzmer, et al.
Pageof 6